Étude d'impact d'un protocole d'antibiothérapie dans les infections cutanées communautaires

Camille Klotz

Université Nice Sophia Antipolis

Faculté de Médecine

THESE D'EXERCICE DE MEDECINE

Pour le

DIPLÔME DU DOCTORAT EN MEDECINE

ETUDE D'IMPACT D'UN PROTOCOLE D'ANTIBIOTHERAPIE DANS LES INFECTIONS CUTANEES COMMUNAUTAIRES

Présentée et soutenue publiquement à la faculté de médecine de Nice

Le 29 mars 2019

Par

Camille KLOTZ

Né le 12 octobre 1989

Devant les membres du jury :

Monsieur le Professeur Raymond RUIMY	Président du jury
Monsieur le Professeur Yann-Erick CLAESSENS	Assesseur
Monsieur le Docteur Pascal DEL GIUDICE	Assesseur
Monsieur le Professeur Gilles GARDON	Assesseur
Monsieur le Professeur Pierre-Marie ROGER	Directeur de thèse

UNIVERSITE NICE SOPHIA ANTIPOLIS
FACULTE DE MEDECINE

Université Nice Sophia Antipolis
Faculté de Médecine

Liste des enseignants au 1er septembre 2018 à la Faculté de Médecine de Nice

Doyen

Pr. BAQUÉ Patrick

Vice-doyens

Pédagogie	**Pr. ALUNNI Véronique**
Recherche	**Pr DELLAMONICA jean**
Etudiants	**M. JOUAN Robin**
Chargé de mission projet Campus	**Pr. PAQUIS Philippe**
Conservateur de la bibliothèque	Mme AMSELLE Danièle
Directrice administrative des services	Mme CALLEA Isabelle
Doyens Honoraires	M. RAMPAL Patrick
	M. BENCHIMOL Daniel

UNIVERSITE NICE SOPHIA ANTIPOLIS
FACULTE DE MEDECINE

Université Nice Sophia Antipolis
Faculté de Médecine

Liste des enseignants au 1er septembre 2018 à la Faculté de Médecine de Nice

PROFESSEURS CLASSE EXCEPTIONNELLE

M.	AMIEL Jean	Urologie (52.04)
M.	BAQUÉ Patrick	Anatomie - Chirurgie Générale (42.01)
M.	BERNARDIN Gilles	Réanimation Médicale (48.02)
M.	BOILEAU Pascal	Chirurgie Orthopédique et Traumatologique (50.02)
M.	DARCOURT Jacques	Biophysique et Médecine Nucléaire (43.01)
M.	ESNAULT Vincent	Néphrologie (52-03)
M.	FENICHEL Patrick	Biologie du Développement et de la Reproduction (54.05)
M.	FUZIBET Jean-Gabriel	Médecine Interne (53.01)
M.	GILSON Éric	Biologie Cellulaire (44.03)
M.	GUGENHEIM Jean	Chirurgie Digestive (52.02)
M.	HASSEN KHODJA Reda	Chirurgie Vasculaire (51.04)
M.	HÉBUTERNE Xavier	Nutrition (44.04)
M.	HOFMAN Paul	Anatomie et Cytologie Pathologiques (42.03)
Mme	ICHAI Carole	Anesthésiologie et Réanimation Chirurgicale (48.01)
M.	LACOUR Jean-Philippe	Dermato-Vénéréologie (50.03)
M.	LEFTHERIOTIS Geogres	Chirurgie vasculaire ; médecine vasculaire (51.04)
M.	MARQUETTE Charles-Hugo	Pneumologie (51.01)
M.	MARTY Pierre	Parasitologie et Mycologie (45.02)
M.	MICHIELS Jean-François	Anatomie et Cytologie Pathologiques (42.03)
M.	MOUROUX Jérôme	Chirurgie Thoracique et Cardiovasculaire (51.03)
Mme	PAQUIS Véronique	Génétique (47.04)
M.	PAQUIS Philippe	Neurochirurgie (49.02)
M.	QUATREHOMME Gérald	Médecine Légale et Droit de la Santé (46.03)
M.	RAUCOULES-AIMÉ Marc	Anesthésie et Réanimation Chirurgicale (48.01)
M.	ROBERT Philippe	Psychiatrie d'Adultes (49.03)
M.	SANTINI Joseph	O.R.L. (55.01)
M.	THYSS Antoine	Cancérologie, Radiothérapie (47.02)
M.	TRAN Albert	Hépato Gastro-entérologie (52.01)

UNIVERSITE NICE SOPHIA ANTIPOLIS
FACULTE DE MEDECINE

Université Nice Sophia Antipolis
Faculté de Médecine

Liste des enseignants au 1er septembre 2018 à la Faculté de Médecine de Nice

PROFESSEURS PREMIERE CLASSE

Mme	ASKENAZY-GITTARD Florence	Pédopsychiatrie (49.04)
M.	BARRANGER Emmanuel	Gynécologie Obstétrique (54.03)
M.	BÉRARD Étienne	Pédiatrie (54.01)
Mme	BLANC-PEDEUTOUR Florence	Cancérologie – Génétique (47.02)
M.	BONGAIN André	Gynécologie-Obstétrique (54.03)
Mme	BREUIL Véronique	Rhumatologie (50.01)
M.	CASTILLO Laurent	O.R.L. (55.01)
M.	CHEVALLIER Patrick	Radiologie et Imagerie Médicale (43.02)
M.	DE PERETTI Fernand	Anatomie-Chirurgie Orthopédique (42.01)
M.	DRICI Milou-Daniel	Pharmacologie Clinique (48.03)
M.	FERRARI Émile	Cardiologie (51.02)
M.	FERRERO Jean-Marc	Cancérologie ; Radiothérapie (47.02)
M.	FONTAINE Denys	Neurochirurgie (49.02)
M.	GIBELIN Pierre	Cardiologie (51.02)
M.	HANNOUN-LEVI Jean-Michel	Cancérologie ; Radiothérapie (47.02)
M.	LEVRAUT Jacques	Médecine d'urgence (48.05)
M.	LONJON Michel	Neurochirurgie (49.02)
M.	MOUNIER Nicolas	Cancérologie, Radiothérapie (47.02)
M.	PADOVANI Bernard	Radiologie et Imagerie Médicale (43.02)
M.	PICHE Thierry	Gastro-entérologie (52.01)
M.	PRADIER Christian	Épidémiologie, Économie de la Santé et Prévention (46.01)
Mme	RAYNAUD Dominique	Hématologie (47.01)
M.	ROSENTHAL Éric	Médecine Interne (53.01)
M.	SCHNEIDER Stéphane	Nutrition (44.04)
M.	STACCINI Pascal	Biostatistiques et Informatique Médicale (46.04)
M.	THOMAS Pierre	Neurologie (49.01)
M.	TROJANI Christophe	Chirurgie Orthopédique et Traumatologique (50.02)

UNIVERSITE NICE SOPHIA ANTIPOLIS
FACULTE DE MEDECINE

Université Nice Sophia Antipolis
Faculté de Médecine

Liste des enseignants au 1er septembre 2018 à la Faculté de Médecine de Nice

PROFESSEURS DEUXIEME CLASSE

Mme	ALUNNI Véronique	Médecine Légale et Droit de la Santé (46.03)
M.	ANTY Rodolphe	Gastro-entérologie (52.01)
M.	BAHADORAN Philippe	Cytologie et Histologie (42.02)
Mme	BAILLIF Stéphanie	Ophtalmologie (55.02)
Mme	BANNWARTH Sylvie	Génétique (47.04)
M.	BENIZRI Emmanuel	Chirurgie Générale (53.02)
M.	BENOIT Michel	Psychiatrie (49.03)
M.	BOZEC Alexandre	ORL- Cancérologie (47.02)
M.	BREAUD Jean	Chirurgie Infantile (54-02)
M.	CHEVALIER Nicolas	Endocrinologie, Diabète et Maladies Métaboliques (54.04)
Mme	CHINETTI Giulia	Biochimie-Biologie Moléculaire (44.01)
M.	CLUZEAU Thomas	Hématologie (47.01)
M.	DELLAMONICA Jean	réanimation médicale (48.02)
M.	DELOTTE Jérôme	Gynécologie-obstétrique (54.03)
M.	FOURNIER Jean-Paul	Thérapeutique (48-04)
Mlle	GIORDANENGO Valérie	Bactériologie-Virologie (45.01)
Mme	GIOVANNINI-CHAMI Lisa	Pédiatrie (54.01)
M.	GUÉRIN Olivier	Méd. In ; Gériatrie (53.01)
M.	IANNELLI Antonio	Chirurgie Digestive (52.02)
M.	ILIE Marius	Anatomie et Cytologie pathologiques (42.03)
M	JEAN BAPTISTE Elixène	Chirurgie vasculaire (51.04)
M.	PASSERON Thierry	Dermato-Vénéréologie (50-03)
M.	ROGER Pierre-Marie	Maladies Infectieuses ; Maladies Tropicales (45.03)
M.	ROHRLICH Pierre	Pédiatrie (54.01)
M.	ROUX Christian	rhumatologie (50.01)
M.	RUIMY Raymond	Bactériologie-virologie (45.01)
Mme	SACCONI Sabrina	Neurologie (49.01)
M.	SADOUL Jean-Louis	Endocrinologie, Diabète et Maladies Métaboliques (54.04)

UNIVERSITE NICE SOPHIA ANTIPOLIS
FACULTE DE MEDECINE

Université Nice Sophia Antipolis
Faculté de Médecine

Liste des enseignants au 1er septembre 2018 à la Faculté de Médecine de Nice

MAITRES DE CONFÉRENCES DES UNIVERSITÉS - PRATICIENS HOSPITALIERS

M.	AMBROSETTI Damien	Cytologie et Histologie (42.02)
M.	BENOLIEL José	Biophysique et Médecine Nucléaire (43.01)
Mme	BERNARD-POMIER Ghislaine	Immunologie (47.03)
M.	BRONSARD Nicolas	Anatomie Chirurgie Orthopédique et Traumatologique (42.01)
Mme	BUREL-VANDENBOS Fanny	Anatomie et Cytologie pathologiques (42.03)
M.	DOGLIO Alain	Bactériologie-Virologie (45.01)
M	DOYEN Jérôme	Radiothérapie (47.02)
M	FAVRE Guillaume	Néphrologie (52.03)
M.	FOSSE Thierry	Bactériologie-Virologie-Hygiène (45.01)
M.	GARRAFFO Rodolphe	Pharmacologie Fondamentale (48.03)
Mme	HINAULT Charlotte	Biochimie et biologie moléculaire (44.01)
M.	HUMBERT Olivier	Biophysique et Médecine Nucléaire (43.01)
Mme	LAMY Brigitte	Bactérilogie-virologie (45.01)
Mme	LONG-MIRA Elodie	Cytologie et Histologie (42.02)
Mme	MAGNIÉ Marie-Noëlle	Physiologie (44.02)
Mme	MOCERI Pamela	Cardiologie (51.02)
M.	MONTAUDIE Henri	Dermatologie (50.03)
Mme	MUSSO-LASSALLE Sandra	Anatomie et Cytologie pathologiques (42.03)
M.	NAÏMI Mourad	Biochimie et Biologie moléculaire (44.01)
Mme	POMARES Christelle	Parasitologie et mycologie (45.02)
M.	SAVOLDELLI Charles	Chirurgie maxillo-faciale et stomatologie (55.03)
Mme	SEITZ-POLSKI barbara	Immunologie (47.03)
M.	TESTA Jean	Épidémiologie Économie de la Santé et Prévention (46.01)
M.	TOULON Pierre	Hématologie et Transfusion (47.01)

UNIVERSITE NICE SOPHIA ANTIPOLIS
FACULTE DE MEDECINE

Université Nice Sophia Antipolis
Faculté de Médecine

Liste des enseignants au 1er septembre 2018 à la Faculté de Médecine de Nice

PROFESSEUR DES UNIVERSITÉS

M.	HOFLIGER Philippe	Médecine Générale (53.03)

MAITRE DE CONFÉRENCES DES UNIVERSITÉS

M.	DARMON David	Médecine Générale (53.03)

PROFESSEURS AGRÉGÉS

Mme	LANDI Rebecca	Anglais

PRATICIEN HOSPITALIER UNIVERSITAIRE

M.	DURAND Matthieu	Urologie (52.04)

PROFESSEURS ASSOCIÉS

M.	GARDON Gilles	Médecine Générale (53.03)
Mme	MONNIER Brigitte	Médecine Générale (53.03)

MAITRES DE CONFÉRENCES ASSOCIÉS

Mme	CASTA Céline	Médecine Générale (53.03)
M.	GASPERINI Fabrice	Médecine Générale (53.03)
M.	HOGU Nicolas	Médecine Générale (53.03)

UNIVERSITE NICE SOPHIA ANTIPOLIS
FACULTE DE MEDECINE

Université Nice Sophia Antipolis
Faculté de Médecine

Liste des enseignants au 1er septembre 2018 à la Faculté de Médecine de Nice

Constitution du jury en qualité de 4ème membre

Professeurs Honoraires

M ALBERTINI Marc
M. BALAS Daniel
M. BATT Michel
M. BLAIVE Bruno
M. BOQUET Patrice
M. BOURGEON André
M. BOUTTÉ Patrick
M. BRUNETON Jean-Noël
Mme BUSSIERE Françoise
M. CAMOUS Jean-Pierre
M. CANIVET Bertrand
M. CASSUTO Jill-patrice
M. CHATEL Marcel
M. COUSSEMENT Alain
Mme CRENESSE Dominique
M. DARCOURT Guy
M. DELLAMONICA Pierre
M. DELMONT Jean
M. DEMARD François
M. DESNUELLE Claude
M. DOLISI Claude
Mme EULLER-ZIEGLER Liana
M . FRANCO Alain
M. FREYCHET Pierre
M. GASTAUD Pierre
M. GÉRARD Jean-Pierre
M. GILLET Jean-Yves
M. GRELLIER Patrick
M. GRIMAUD Dominique
M. HARTER Michel
M. JOURDAN Jacques
M. LAMBERT Jean-Claude
M. LAZDUNSKI Michel
M. LEFEBVRE Jean-Claude
M. LE FICHOUX Yves
Mme LEBRETON Elisabeth
M. MARIANI Roger
M. MASSEYEFF René
M. MATTEI Mathieu
M. MOUIEL Jean
Mme MYQUEL Martine
M. ORTONNE Jean-Paul
M. PRINGUEY Dominique
M. SAUTRON Jean Baptiste
M. SCHNEIDER Maurice
M. TOUBOL Jacques
M. TRAN Dinh Khiem
M VAN OBBERGHEN Emmanuel
M. ZIEGLER Gérard

M.C.U. Honoraires

M. ARNOLD Jacques
M. BASTERIS Bernard
Mlle CHICHMANIAN Rose-Marie
Mme DONZEAU Michèle
M. EMILIOZZI Roméo
M. FRANKEN Philippe
M. GASTAUD Marcel
M. GIUDICELLI Jean
M. MAGNÉ Jacques
Mme MEMRAN Nadine
M. MENGUAL Raymond
M. PHILIP Patrick
M. POIRÉE Jean-Claude
Mme ROURE Marie-Claire

Remerciements

Tout d'abord merci à Pierre-Marie de m'avoir fait confiance en me proposant ce travail. Merci pour ta disponibilité et ton accompagnement tout le long de sa réalisation, la rédaction, les statistiques et pour sa publication. Merci à Céline, Johan, Elisa et Raymond pour votre participation à ce papier et vos bons conseils qui ont permis de l'améliorer jusqu'ici.

Merci également à tous les membres du jury d'avoir accepté de venir évaluer mon travail.

Un très grand merci à toute ma famille d'avoir cru en moi depuis que je me suis lancé dans les études de médecine. Votre soutien a toujours été précieux pour moi, je m'y suis accroché dans les moments de doute et de fatigue. Merci à tous ceux qui ont fait le déplacement depuis Rabat ou Casablanca pour venir assister à cette soutenance, j'en suis profondément touché sachant toute l'organisation logistique que cela implique. Merci aussi à ceux qui n'ont pas pu se déplacer mais qui auraient aimé être présents.

Merci à Amina, May, Leïla, Allal et Hamza de m'avoir servi d'exemple. Je tacherai de ne pas vous décevoir dans ma pratique future.

Merci à Véronique, David, Karine pour votre confiance et vos encouragements. Un merci en particulier à Éric, qui m'a donné envie de m'orienter vers l'infectiologie.

Je me dois aussi de remercier toute l'équipe soignante du service d'infectiologie, vous êtes tous géniaux, sans exception. N'oubliez pas que sans vous, rien ne serait possible, et toutes nos prescriptions aussi savantes soient-elles ne seraient que du vent. J'admire sincèrement votre courage et votre dévouement pour les malades malgré des conditions de travail rendues de plus en plus pénibles par les restrictions de moyens toujours plus lourdes.

Merci à Nico et Jon, pour ces innombrables fous rires thérapeutiques, les plus dingues que j'ai pu vivre, et pour les moments moins drôles aussi. J'espère qu'on continuera encore longtemps à pleurer de rire ensemble et à être là les uns pour les autres pour les coups durs.

Merci aussi à Alex, Arda, Guigui, Débo, Julien, Céline, Thom, Aurore, Micka, Mad, Tutur, César, Maddy, Nath, Thib, Estelle, Albert, Greg, Célia (il y en a deux !), Zoé, Charles, Diane, Kamel, Pandi, Joël, Gros, Verdun, Michel, Biche, Matoy, Pierre, Ben, Xav, Charline, Etienne, Antoine, Julie, Victoria, Charley et à tous les autres amis avec qui j'ai passé tous ces bons moments. Je n'ai malheureusement pas la place de tous vous nommer pour des raisons écologiques évidentes. Ne soyez pas lésé(e) si votre nom ne figure pas sur cette longue liste. Si toutefois vous l'êtes, on peut toujours arranger ça avec un…

Enfin, merci à Marion. Merci de m'avoir supporté depuis un peu plus de trois ans. Tu m'as vu traverser tout mon internat et tu as su garder cette patience tout le long. Tu as été là pour moi malgré la distance qui nous a séparés pendant presque 3 ans. Tu as tenu bon malgré mon humeur parfois (souvent) pénible. Tu as eu le courage de quitter ta terre natale et ta famille pour me rejoindre. J'espère que nos chemins se suivront encore longtemps car je suis vraiment chanceux de partager la vie d'une personne aussi géniale que toi.

Table des matières

Résumé synthétique du travail :

En dehors des zones de prévalence du Staphylocoque doré résistant à la méthicilline dans la communauté, il n'y a à notre connaissance aucun travail ayant étudié le lien entre le traitement antibiotique des érysipèles ou des cellulites, et l'évolution clinique des patients. L'objectif de cette étude était donc de mesurer l'impact d'un protocole interne d'antibiothérapie sur la morbi-mortalité.

Cette étude était basée sur le tableau de bord du service des maladies infectieuses du CHU de Nice. Il s'agit d'une base de données enregistrant 28 paramètres pour tous les patients hospitalisés dans le service. Nous avons inclus les patients admis pour érysipèle ou cellulite d'origine communautaire ; les critères d'exclusion étaient les infections nécrotiques ou abcédées d'emblée ; les cellulites à porte d'entrée ORL ou dentaire ; les infections consécutives aux morsures animales ; les pyomyosites ; et les durées de séjour inférieures ou égales à deux jours (considérant qu'il s'agissait d'une erreur d'orientation ou d'une hospitalisation injustifiée). Le respect du protocole, basé sur les recommandations nationales, a été défini par l'utilisation de l'amoxicilline, de l'amoxicilline-acide clavulanique, de la clindamycine, ou de la pristinamycine, en monothérapie ou en association ou successivement. Une évolution défavorable était définie par la nécessité de recours à la chirurgie (par exemple : drainage d'abcès, amputation, excision de nécrose) de transfert en réanimation ou la mortalité, survenant après cinq jours ou plus d'antibiothérapie.

De juillet 2005 à juin 2017, 630 cas d'érysipèle ou de cellulite ont été inclus. Les hémocultures effectuées chez 567 patients (90 %) étaient positives dans 39 cas (6,9 %), dont 33 à Streptocoques. Le taux d'antibiothérapies adhérentes au protocole était de 65 % (410 cas). Une évolution défavorable a été enregistrée chez 54 patients (8,5 %), moins fréquemment en cas de conformité au protocole : 26/410 (6,3%) vs 28/220 (12,7%), p = 0,007. En analyse multivariée, deux facteurs de risque étaient associés à une évolution défavorable : l'artériopathie oblitérante des membres inférieurs, AOR 4,80 (2,20-10,49) et la bactériémie, AOR 5,21 (2,31-11,76), tandis que le respect du protocole était le seul facteur protecteur modifiable, OR 0,48 (0,26-0,89).

En conclusion, dans les érysipèles et cellulites communautaires non abcédées et non nécrosantes, le respect du protocole était associé à un risque plus faible d'évolution défavorable. L'utilisation de l'amoxicilline-acide clavulanique semble être un choix sûr dans ces infections en cas d'incertitude sur l'étiologie streptococcique.

Adherence to antibiotic guidelines for erysipelas or cellulitis is associated with a favourable outcome

Camille Klotz[1], Johan Courjon[1,2], Céline Michelangeli[1], Elisa Demonchy[1], Raymond Ruimy[2,3], Pierre-Marie Roger[1,2,4]

1. Infectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France

2. Faculté de Médecine, Université de Nice Sophia-Antipolis, France

3. Bactériologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France

4. Groupe Elsan, Rue de la Boétie, 75008, Paris

Title: 14 words

Summary: 256 words

Words including manuscript with references: 2048 words

Correspondence:

Camille Klotz

Infectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France

Abstract

Purpose

Outside areas of *S. aureus* strains resistant to methicillin (MRSA) in the community, no studies showed a relationship between the treatment for erysipelas or cellulitis and the outcome. We aimed to measure the impact of an internal therapeutic protocol, based on national guidelines on patients' outcome.

Methods

This study was based on the dashboard of the infectious diseases department, which prospectively includes 28 parameters for all admitted patients. We included community acquired erysipelas and cellulitis; exclusion criteria were abscesses at admission, ear nose throat or dental cellulitis, pyomyositis and length of stay ≤ 2 days. Adherence to guidelines was defined by the use of amoxicillin, amoxicillin/clavulanic acid, clindamycin or pristinamycin, alone or in combination or successively. A poor outcome was defined by surgical procedure or intensive care requirement or death occurring after 5 days or more of antibiotic therapy.

Results

From July 2005 to June 2017, 630 cases of erysipelas or cellulitis were included. Blood cultures performed in 567 patients (90%) were positive in 39 cases (6.9%). Adherence rate to guidelines was 65% (410 cases). A poor outcome was recorded in 54 (8.5%) patients, less frequently in case of adherence to guidelines: 26/410 (6.3%) *vs* 28/220 (12.7%), p = 0.007. In logistic regression analysis, 2 risk factors were associated with a poor outcome: peripheral arterial disease: AOR 4.80 [2.20 – 10.49] and bacteraemia: AOR 5.21 [2.31 - 11.76], while guideline adherence was the only modifiable protective factor: OR 0.48 [0.26 - 0.89].

Conclusion

In erysipelas and cellulitis, adherence to guidelines was associated with a favourable outcome.

Keywords: erysipelas; cellulitis; SSTI; antibiotic therapy; guidelines; outcome

Erysipelas and cellulitis are frequent cutaneous skin and soft tissue infections (SSTI) that lead to hospitalizations due to the disease and/or patients' comorbid conditions [1,2]. Thus, several guidelines have been published worldwide to help the clinicians with antibiotic prescription. The French guidelines published in 2000 [1] focusing on erysipelas and necrotizing fasciitis highlighted the main role of *Streptococcus pyogenes* and indicated a short selection of antibiotic treatments to be used in these infections. Amoxicillin is recommended for erysipelas, plus clindamycin or rifampicin in case of necrotizing fasciitis, amoxicillin + clavulanic acid in case of IV drug use and finally pristinamycin in case of penicillin allergy. These recommendations are based on microbial and clinical data.

Since 2000, there was no significant change in microbial epidemiology in erysipelas and cellulitis in France, which differs from the United States of America [2,3,4]. More particularly, we do not observe the emergence of *S. aureus* strains resistant to methicillin (MRSA) in the community in France, in contrast with its high prevalence in US.

More than fifteen years after the French guideline publication, few studies have reported the antibiotic use in erysipelas and cellulitis [2,5-9]. Moreover, as far as we know, there is no study assessing the impact of this guidelines on morbidity and mortality of patients presenting with erysipelas or cellulitis. The aim was to study the relationship between physicians' adherence to an hospital-based antibiotic protocol, according to the French guideline for erysipelas and cellulitis, and patients' outcome.

Methods

Patient selection and data collection

We conducted a cohort study at the University Hospital of Nice, France, a tertiary care centre with a single infectious diseases department. This study was based on data collected through the department's medical dashboard put into practice since July 2005 [10]. This dashboard works as a large database for observational studies. It is declared to the French Data Protection Authority, number 1430722.

It prospectively records 28 parameters for all hospitalized patients, including initial and final diagnosis, comorbid conditions, microbiological data, antibiotic therapy, adverse effects and outcome. Comorbid conditions were defined by their specific treatment at admission or newly diagnosed during hospital stay.

We selected all cases of community-acquired erysipelas or cellulitis from the 1st of July 2005 to the 30th of June 2017, healthcare-associated infections being defined a diagnosis established ≥ 48 h after hospital admission or when observed less than one month after surgery and less than one year in case of surgical device implantation.

For this study we have specifically verified in the patient's chart the accuracy of the blood culture's results and community-acquired characteristics of the infection when the bacteria were reputed for its nosocomial features such as antimicrobial-resistant *Enterobacteriaceae* or *Pseudomonas aeruginosa*.

We excluded patients with abscess or necrosis or pyomyositis requiring a surgical approach at admission or in the first 5 days in hospital, considering that those complications requiring surgical procedure were already present at admission. Also, infections following animal bite, ear nose throat (ENT) or dental origin were excluded. Lastly, patients with length of stay ≤ 2 days were excluded considering that hospitalization in the infectious diseases department was unnecessary or inappropriate.

Protocol adherence

In the infectious diseases department, the internal protocol for erysipelas and cellulitis was defined in April 2009. It was based on the French national guidelines published in year 2000. Those official guidelines have not been changed or revised since then. We proposed to use amoxicillin alone in case of non-necrotizing infections. In case of penicillin allergy, we proposed to use pristinamycin alone. This choice was based on microbial data highlighting the main prevalence of *S. pyogenes* in those infections. In case of IV drug use or traumatic wound, we proposed to use amoxicillin + clavulanic acid in aim to cover Methicillin-Sensible

Staphylococcus aureus (MSSA). Lastly, in case of severe case or suspicion of necrotizing form of infections, clindamycin was recommended in combination with other molecules. This choice was based on data suggesting the benefit of clindamycin to inhibit the harmful effect of bacterial toxins [11].

Protocol adherence was defined by the use of amoxicillin, amoxicillin/clavulanic acid, clindamycin or pristinamycin, alone or in a combination or successively.

Poor outcome was a composite criterion, defined by the need of surgical procedure and/or transfer to intensive care unit (ICU) and/or death at least after 5 days of antibiotic treatment. This outcome was recorded at any moment of the hospitalization until discharge.

Statistical analysis

The data were analysed with Statview® software version 5.0 and statistical significance was established at $\alpha = 0.05$. We used Mann–Whitney non-parametric test, and the $\chi 2$ or Fisher's exact test, when appropriate. Logistic regression was used for multivariate analysis of the impact of guideline adherence on all causes of unfavourable outcome, and results are presented as adjusted odds ratios (AORs) with their 95% confidence intervals (CIs).

Variables were selected as candidates in multivariate analysis on the basis of the level of significance of the univariate association with unfavourable outcome ($p \leq 0.1$).

Results

Epidemiology of erysipelas and cellulitis

From July 2005 to June 2017, 514 cases of erysipelas and 116 cases of cellulitis were included in the study according to successive selection criteria (see Figure 1-A). The most frequent comorbid conditions were diabetes (95 cases, 15%), liver diseases (72 cases, 11%) and venous insufficiency (72 cases, 11%). The patients with erysipelas were older ($p < 0.001$) and presented more frequently with venous insufficiency ($p = 0.043$) compared to patients with cellulitis. The clinical presentation was also different, erysipelas being more often localized on inferior limbs than cellulitis, 86% *vs* 57%, $p < 0.001$.

Microbiological data

Blood cultures were performed in 567 patients (90%), and 39 were positive (7%), including 33 cases of streptococci (85%), 3 cases of *Enterobacteriaceae* (8%), 2 cases of *Pseudomonas* (5%), and only one *Staphylococcus aureus* (3%). There was no significant difference between both groups. No other germs were isolated in bacteraemic patients. The only case of *S. aureus* was susceptible to methicillin. Both cases of *P. aeruginosa* were susceptible to Cefepime and Meropenem, one was susceptible to Tazocillin and the other was intermediate. Concerning the 3 recorded cases of *Enterobacteriaceae*, there was no case of ESBL production or cephalosporinase hyper production.

Therapeutic means

The two most used antibiotics were amoxicillin alone (271 cases, 43%) and amoxicillin/clavulanic acid (71 cases, 11%). Protocol adherence was recorded in 410 (65%) cases, being higher in erysipelas compared to cellulitis: 73% *vs* 29%, p <0.001. Antibiotic therapies differing from the protocol (n = 220, 35%) were assessed through the patient's chart analysis and were explained in 66/220 cases (30%). Microbial data were the main source of deviation from the protocol: 27/66 cases (41%), especially in case of cellulitis.

Outcome and impact of adherence to antibiotic protocol

Unfavourable outcome was less frequently observed in erysipelas compared to cellulitis: 37 (7%), *vs* 17 (15%), p = 0.01. Surgery procedure requirement was significantly more frequent in case of non-adherent treatment: 12/410 (3%) *vs* 19/220 (9%); p = 0.002. Surgical procedures included drainage (n = 12), necrosis excisions (n = 8), amputation (n = 5), angioplasty (n = 3), skin graft (n = 2) or arthroscopic lavage (n = 1).

We also observed a trend towards more ICU requirements and ultimately deaths in case of non-adherent treatment (see Table 1). Thus, according to the study's definition, an unfavourable outcome was observed in 54 (8.5%) patients, more frequently in case of non-adherent treatment: 28/220 (13%) *vs* 26/410 (6%), p = 0.007.

In multivariate analysis (see Table 2), the 2 risk factors associated with unfavourable outcome were peripheral arterial disease (AOR 4.80 [2.20 – 10.49]) and bacteraemia (AOR 5.21 [2.31 - 11.76]). Protocol adherence was protective of unfavourable outcome: OR 0.48 [0.26 - 0.89], p = 0.007.

Discussion

This cohort study over 12 years shows a better outcome for adult patients admitted for erysipelas or cellulitis when adherence to antibiotic protocol was observed. The risk of poor outcome was almost doubled in case of non-adherent treatment. This composite criterion seems to be appropriate as it reflects severe complications in erysipelas and cellulitis. The univariate analysis indicated that surgical requirement was the main element of poor outcome. Besides, other results indicated that peripheral arterial disease as well as bacteraemia were associated with a poorer outcome.

This study has several limitations. The main one is that we were unable investigate the exact reasons for non-adherent prescriptions. Extensive analysis of the patient's chart revealed that only one third of non-adherent prescriptions 66/220 (30%) were explained by physician. Moreover, the dashboard does not assess the initial severity of the infection, which may explain the discrepancies between guidelines and senior physicians' prescriptions. However, the data suggest that, except the microbiological reassessment of the empirical antimicrobial treatment, there is no benefit to deviate from guidelines. Also, the database did not record antibiotic therapies received prior hospital admission. However, in France most of erysipelas and cellulitis receive the first course of antibiotic in hospital [2]. Another limit is the inclusion of both erysipelas and cellulitis, those are two clinical entities have several differences in pathophysiology, and causal bacteria. However, this study and others indicated no significant difference in term of causal bacteria [12]. Also, current classification includes these 2 entities under the same terminology "non-necrotizing acute bacterial skin and structure infections" [13].

In the infectious diseases department, the global adherence to the protocol was 65%, being higher in erysipelas (73%). Pulido-Cejudo *et al* underlined on the heterogeneity in skin and soft tissue infection management as well as the high frequency of inappropriate antibiotic therapy, > 20% of the cases [13]. Thus, the high incidence of erysipelas and cellulitis suggests that a better use of antibiotics in skin and soft tissue infections may have a favourable ecological impact.

Very few studies aimed to assess the relationship between recommended antibiotic therapy and outcome. Inappropriate antibiotic therapy for skin and soft tissue infections has been associated at least with prolonged duration of hospitalisation stay and more surgical requirement [13,14]. Yet, Figtree *et al* reported a retrospective analysis of 395 episodes of cellulitis and erysipelas with a mortality rate of 2.5%, in which bacteraemia was also associated with a fatal outcome [15]. However, the authors did not study the impact of the antibiotic treatment on the outcome, even if infectious disease physician input was associated with more frequent use of a first-generation cephalosporin empirically and less frequently the combination of penicillin and flucloxacillin. Also, in that study, a surgical procedure was required in 87 cases (22%), which is far more than what we observed: the difference might be due to the exclusion criteria, considering surgical procedure requirement before 5 days of antibiotic therapy as the reflect of undetected abscess, collection or necrosis at admission. These exclusion criteria may appear in contradiction with recent positions suggesting that the antibiotic efficiency should be evaluated 48-72 h after initiation of therapy [3,16]. But the way to optimize the management of clinical failure is not acutely determined.

In multivariate analysis, peripheral arterial disease was associated with a poor outcome as previously reported [15,13]. As an explanation, peripheral arterial disease leads to poor antibiotic delivery in infected tissue and/or necrosis [17].

Bacteraemia, searched in 90% of the patients, was observed in 7% in this study. Its relationship with poor outcome was observed in several situations such as respiratory or bone

infections [18, 19]. These data argue for systematic microbial investigations including blood cultures. Bacterial results, at least from blood cultures, demonstrate the major implication of streptococci, validating the appropriateness of the current French antibiotic guideline, and extensively of the internal protocol. Of note, in this study no MRSA was detected, indicating the need for national bacteriological survey to establish recommendations. Accordingly, current antibiotic guideline is adequate in community-acquired erysipelas and cellulitis in which *Streptococcus spp* are still predominant. At least in France, amoxicillin + clavulanic acid seems to be a safe choice in case of doubts between these 2 clinical entities.

Compliance with ethical standards

Funding: none

Conflict of Interest: All of the authors declare that they have no conflicts of interest. Ethics approval: Observational studies don't require ethical approval in France. Antimicrobial stewardship is promoted by the French National Health Agency. Internal dashboard is declared to French Data Protection Authority, number 1430722. Informed consent: patients or their relatives provided their written consent for digitization of their personal data for hospitalization purposes.

References

1. Erysipèle et fasciite nécrosante. Prise en charge. Conférence de consensus (2000) *Med Mal Inf.* 30(Suppl 4):252-72
2. Bernard P, Christmann D, Morel M (2005) Management of erysipelas in French hospitals: a post-consensus conference study. *Ann Dermatol Venereol*. 132:213-7
3. Food and Drug Administration. Guidance for industry: acute bacterial skin and skin structure infections developing drugs for treatment (2013) www.fda.gov/downloads/Drugs/./Guidances/ ucm071185.pdf. accessed 24 August 2016
4. Sartelli M, Malangoni MA, May AK, Viale P, Kao LS, Catena F, et al (2014) WSES guidelines for management of SSTI, World journal of emergency surgery. 9:57
5. Kamath RS, Sudhakar D, Gardner JG, Hemmige V, Safar H, Musher DM (2018) Guidelines vs Actual Management of Skin and Soft Tissue Infections in the Emergency Department. Open Forum Infect Dis. 5(1):ofx188
6. Jenkins TC, Knepper BC, Moore SJ, O'Leary ST, Caldwell B, Saveli CC, et al (2014) Antibiotic Prescribing Practices in a Multicenter Cohort of Patients Hospitalized for Acute Bacterial Skin and Skin Structure Infection. Infect Control Hosp Epidemiol. 35(10):1241-50
7. Lazzarini L, Conti E, Tositti G, Lalla F (2005) Erysipelas and cellulitis: clinical and microbiological spectrum in an Italian tertiary care hospital. J Infect. 51(5):383-9
8. Lipsky BB, Napolitano LM, Moran GJ, Vo L, Nicholson S, Kim M (2014) inappropriate initial antibiotic treatment for complicated skin and soft tissue infections in hospitalized patients: incidence and associated factors. Diagn Microbiol Infect Dis. 79(2):273-9

9. Walsh TL, Chan L, Konopka CI, Burkitt MJ, Moffa MA, Bremmer DN, et al (2016) Appropriateness of antibiotic management of uncomplicated SSTIs in hospitalized adult patients. BMC Infect Dis. 16(1):721
10. Roger PM, Demonchy E, Risso K, Courjon J, Leroux S, Leroux E, et al (2017) Medical table: A major tool for antimicrobial stewardship policy. Med Mal Infect. 47(5):311-8
11. Marek Smieja (1998) MD FRCPC DTM&H, Current indications for the use of clindamycin: A critical review, Canadian J infect. Dis. 9(1):22-8
12. Gunderson CG, Martinello RA (2012) A systematic review of bacteraemia in cellulitis and erysipelas. J Infect. 64(2):148-55
13. Pulido-Cejudo A, Guzmán-Gutierrez M, Jalife-Montaño A, Ortiz-Covarrubias A, Martínez-Ordaz JL, Noyola-Villalobos HF, et al (2017) Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Ther Adv Infect Dis. 4(5):143-61
14. Halilovic J, Heintz BH, Brown J (2012) Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect. 65(2):128-34
15. Figtree M, Konecny P, Jennings Z, Goh C, Krilis SA, Miyakis S (2010) Risk stratification and outcome of cellulitis admitted to hospital, J Infect. 60(6):431-9
16. Corey GR, Stryjewski ME (2011) New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. *Clin Infect Dis*. 52(*Suppl*. 7):S469-76
17. Joukhadar C, Klein N, Frossard M, Minar E, Stass H, Lackner E, et al. (2001) Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. *Clin Pharmacol Ther*. 70(6):532-9
18. Roger PM, Cua E, Courjon J, Landraud L, Carles M, Bernard E (2014) The impact of bacteraemia on the outcome of bone infections. *Med Mal Infect*. 44(8):380-6

19. Vazquez-Grande G, Kumar A (2015) Optimizing antimicrobial therapy of sepsis and septic shock: focus on antibiotic combination therapy. *Semin Respir Crit Care Med* 36(1):154-66

Figure 1-A: Flow chart



Figure 1-B: Patients with poor outcome



Table 1: Main characteristics of the patients according to the guideline's adherence.

	Adherence n = 410 (65%)	**Non-adherence n = 220 (35%)**	**p**
Age (years ± standard deviation)	66±18	58±20	<0.001
Sex-ratio (M/F)	1.39	2.16	0.013
Final diagnosis			
Erysipelas	375 (92)	139 (63)	<0.001
Cellulitis	34 (8)	82 (37)	<0.001
Comorbidities			
Liver disease	40 (10)	32 (14)	0.077
Alcoholism	40 (10)	27 (12)	0.344
Diabetes	61 (15)	34 (15)	0.875
Venous insufficiency	46 (11)	26 (12)	0.845
Active cancer	34 (8)	18 (8)	0.942
Peripheral arterial disease	25 (6)	20 (9)	0.172
IV drug use	18 (4)	27 (12)	<0.001
Penicillin Allergy	8 (2)	11 (5)	0.034
Infection site			
Lower limb	348 (85)	159 (72)	<0.001
Upper limb	41 (10)	30 (14)	0.179
head	13 (3)	21 (10)	<0.001
others	7 (2)	11 (5)	0.019
Microbiological data			
Blood cultures performed	367 (89)	200 (91)	0.577
Bacteremia, n= 39 (6.2%)	27 (6.5)	12 (6)	0.541
Streptococci, n = 33	27 (6.5)	6 (3)	<0.001
Staphylococcus aureus, n = 1	0	1	
Others, n = 5	0	5	
Antibiotic prescription			
amoxicillin alone	271 (66)	0	<0.001
amoxicillin + clindamycin	18 (4)	3 (1)	0.072
clindamycin alone	6 (1)	7 (3)	0.152
pristinamycin alone	24 (6)	0	<0.001
amoxicillin + clavulanic acid	55 (13)	15 (7)	0.011
other first line antibiotics	59 (14)	205 (93)	<0.001
≥ 2 successive antibiotics	33 (8)	131 (59)	<0.001
Reasons for non-adherent treatment			
- microbial data	na*	27 (41)	
- comorbidities/medical file	na	14 (21)	
- associated diagnosis	na	17 (26)	
- treatment failure	na	8 (12)	
Length of stay (days ± std dev)	**7.4±5.4**	**10±6.2**	**<0.001**
Poor outcome	**26 (6)**	**28 (13)**	**0.007**
Death	12 (3)	10 (5)	0.299
Transfer to ICU	5 (1)	6 (3)	0.296
Surgery requirement	12 (3)	19 (9)	0.002

*na = none applicable

Table 2: Risk factors for a poor outcome. The latter was defined as surgery requirement (n = 31) and/or transfer to intensive care unit (n = 11) and/or death (n = 22).

	Favourable outcome n = 576 (91.4%)	**Poor outcome n = 54 (8.6%)**	**p**	**AOR**
Age (years ± standard deviation)	63±19	69±17	0.017	
Sex-ratio (M/F)	1.62	1.57	0.920	
Final diagnosis				
Erysipelas	477 (83)	37 (69)	0.010	
Cellulitis	99 (17)	17 (31)	"	
Comorbidities				
Liver disease	64 (11)	8 (15)	0.413	
Alcoholism	59 (10)	8 (15)	0.297	
Diabetes	82 (14)	13 (24)	0.053	
Venous insufficiency	65 (11)	7 (13)	0.711	
Active cancer	46 (8)	6 (11)	0.425	
Peripheral arterial disease	32 (6)	13 (24)	< 0.001	4.80 [2.20-10.49]
IV drug use	41 (7)	4 (7)	> 0.999	
Penicillin Allergy	18 (3)	1 (2)	0.915	
Infection site				
Lower limb	462 (80)	45 (83)	0.580	
Upper limb	67 (12)	4 (7)	0.475	
head	32 (5)	2 (4)	0.794	
others	15 (3)	3 (6)	0.414	
Microbial data				
Blood culture performed, n = 567 (90%)	518 (90)	49 (91)	0.849	
Bacteremia, n = 39	28 (5)	11 (22)	< 0.001	5.21 [2.31-11.76]
Streptococci, n = 33	27 (4.5)	6 (11)	0.005	
Staphylococcus aureus, n = 1	0	1		
Others, n = 5	1	4		
Adherence to protocol, n = 410 (65%)	384 (66)	26 (48)	0.007	0.48 [0.26-0.89]